T. Ishikawa

Intranasal Immunization with a Formalin-Inactivated Human Influenza A Virus Whole-Virion Vaccine Alone and Intranasal Immunization with a Split-Virion Vaccine with Mucosal Adjuvants Show Similar Levels of Cross-Protection

M. Akashi, T. Akagi, K. Yamanishi, 2012, Clinical and Vaccine Immunology.

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine

M. Tashiro, Tadaki Suzuki, T. Sata, 2012, Journal of medical virology.

Poly-γ-Glutamic Acid Nanoparticles and Aluminum Adjuvant Used as an Adjuvant with a Single Dose of Japanese Encephalitis Virus-Like Particles Provide Effective Protection from Japanese Encephalitis Virus

M. Akashi, T. Akagi, K. Yamanishi, 2011, Clinical and Vaccine Immunology.

Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.

K. Yamanishi, K. Hayashida, Y. Gomi, 2015, Journal of immunological methods.

Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.

Mitsuru Akashi, Yasuko Mori, Shigefumi Okamoto, 2009, Vaccine.

Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.

M. Akashi, T. Akagi, K. Yamanishi, 2007, Vaccine.

Monoclonal antibodies in man that neutralized H3N2 influenza viruses were classified into three groups with distinct strain specificity: 1968-1973, 1977-1993 and 1997-2003.

Y. Iba, Y. Kurosawa, T. Yoshikawa, 2010, Virology.